Level Four Advisory Services LLC Purchases 5,103 Shares of Novartis AG (NYSE:NVS)
Level Four Advisory Services LLC Purchases 5,103 Shares of Novartis AG (NYSE:NVS)
Level Four Advisory Services LLC lifted its position in Novartis AG (NYSE:NVS – Get Rating) by 60.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,565 shares of the company's stock after buying an additional 5,103 shares during the quarter. Level Four Advisory Services LLC's holdings in Novartis were worth $1,190,000 as of its most recent filing with the SEC.
根據Level Four Consulting Services LLC在最近提交給美國證券交易委員會的13F文件中顯示，該公司在第一季度將其在諾華製藥(紐約證券交易所代碼：NVS-GET評級)的持倉上調了60.3%。該機構投資者在本季度額外購買了5,103股後，持有該公司13,565股股票。截至最近提交給美國證券交易委員會的文件，Level Four Consulting Services LLC持有的諾華股份價值119萬美元。
Other large investors have also made changes to their positions in the company. Atwood & Palmer Inc. lifted its holdings in Novartis by 400.0% in the 1st quarter. Atwood & Palmer Inc. now owns 375 shares of the company's stock worth $33,000 after purchasing an additional 300 shares during the last quarter. Allegheny Financial Group LTD acquired a new stake in Novartis in the 4th quarter worth approximately $34,000. DeDora Capital Inc. acquired a new stake in Novartis in the 1st quarter worth approximately $34,000. Tyler Stone Wealth Management acquired a new stake in Novartis in the 4th quarter worth approximately $39,000. Finally, Crewe Advisors LLC lifted its holdings in Novartis by 678.0% in the 4th quarter. Crewe Advisors LLC now owns 459 shares of the company's stock worth $40,000 after purchasing an additional 400 shares during the last quarter. Institutional investors own 9.40% of the company's stock.
其他大型投資者也改變了他們在該公司的頭寸。今年第一季度，阿特伍德-帕爾默公司增持了400.0%的諾華股份。Atwood&Palmer Inc.現在持有375股該公司股票，價值33,000美元，在上個季度又購買了300股。阿勒格尼金融集團有限公司在第四季度收購了諾華公司價值約3.4萬美元的新股份。DeDora Capital Inc.在第一季度收購了諾華公司價值約3.4萬美元的新股份。泰勒·斯通財富管理公司在第四季度收購了諾華公司價值約3.9萬美元的新股份。最後，Crewe Advisors LLC在第四季度增持了678.0%的諾華股份。Crewe Advisors LLC現在持有該公司459股股票，價值4萬美元，在上個季度又購買了400股。機構投資者持有該公司9.40%的股份。
Analysts Set New Price Targets
分析師設定新的價格目標
NVS has been the subject of several analyst reports. UBS Group boosted their target price on Novartis from CHF 85 to CHF 88 and gave the stock a "neutral" rating in a report on Wednesday, April 27th. Wolfe Research lowered Novartis from an "outperform" rating to a "market perform" rating in a report on Monday, May 9th. Credit Suisse Group upped their price target on Novartis from CHF 85 to CHF 88 in a report on Thursday, April 28th. JPMorgan Chase & Co. upped their price target on Novartis from CHF 80 to CHF 81 and gave the stock an "underweight" rating in a report on Wednesday, July 20th. Finally, Oppenheimer lowered Novartis from an "outperform" rating to a "market perform" rating in a report on Friday, June 3rd. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $87.33.
NVS一直是幾份分析師報告的主題。瑞銀集團在4月27日週三的一份報告中將諾華公司的目標價從85瑞士法郎上調至88瑞士法郎，並給予該股“中性”評級。沃爾夫研究公司在5月9日星期一的一份報告中將諾華公司的評級從“跑贏大盤”下調至“市場表現”。瑞士信貸集團在4月28日星期四的一份報告中將諾華的目標價從85瑞士法郎上調至88瑞士法郎。摩根大通在7月20日星期三的一份報告中將諾華公司的目標價從80瑞士法郎上調至81瑞士法郎，並將該股的評級定為“減持”。最後，在6月3日星期五的一份報告中，奧本海默將諾華的評級從“跑贏大盤”下調至“市場表現”。兩名研究分析師對該股的評級為賣出，8名分析師給予持有評級，3名分析師給予買入評級，一名分析師給予該公司強烈買入評級。根據MarketBeat.com的數據，該公司目前的普遍評級為持有，平均目標價為87.33美元。
Novartis Stock Performance
諾華公司股票表現
Novartis (NYSE:NVS – Get Rating) last announced its quarterly earnings results on Monday, July 18th. The company reported $1.56 earnings per share for the quarter, beating analysts' consensus estimates of $1.52 by $0.04. Novartis had a return on equity of 21.88% and a net margin of 44.31%. The firm had revenue of $12.78 billion for the quarter, compared to analysts' expectations of $12.78 billion. During the same period in the prior year, the business posted $1.64 earnings per share. The business's revenue was down 1.4% compared to the same quarter last year. Sell-side analysts forecast that Novartis AG will post 6.06 EPS for the current year.
諾華公司(紐約證券交易所代碼：NVS-GET Rating)上一次公佈季度收益是在7月18日星期一。該公司公佈本季度每股收益為1.56美元，比分析師普遍預期的1.52美元高出0.04美元。諾華的股本回報率為21.88%，淨利潤率為44.31%。該公司當季營收為127.8億美元，高於分析師預期的127.8億美元。去年同期，該業務公佈的每股收益為1.64美元。與去年同期相比，該業務的收入下降了1.4%。賣方分析師預計，諾華製藥本年度每股收益將達到6.06。
Novartis Profile
諾華簡介
(Get Rating)
(獲取評級)
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
諾華製藥在全球研究、開發、製造和營銷保健品。該公司通過兩個部門運營，創新藥品和Sandoz。創新藥品部門為患者和醫療保健提供者提供處方藥。它還提供眼科、神經科學、免疫學、肝科、皮膚科、呼吸科、心血管、腎臟和新陳代謝藥物產品。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- MarketBeat: Week in Review 8/8 – 8/12
- 2 Important Retail Stock Battles to Watch
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免費獲取StockNews.com關於諾華(Novartis)的研究報告
- MarketBeat：回顧中的一週2012-8-8
- 值得關注的兩場重要的零售股大戰
- 什麼是WallStreetBets，他們的目標是什麼股票？
- 機構和分析師推動Jack in the Box走高
- 你能猜到哪個電動車股票打敗了特斯拉嗎？
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
接受諾華日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對諾華和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。